Repligen | RGEN - Current Liabilities


Repligen reported $132.66M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
Agilent USD 2.29B 20M Jun/2026
Align Technology USD 1.91B 2.74M Jun/2026
Bio Techne USD 163.7M 10.42M Jun/2026
BioMarin Pharmaceutical USD 1.66B 870.84M Jun/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Bruker USD 1.2B 150.4M Jun/2026
Charles River Laboratories USD 1.13B 41.04M Jun/2026
Danaher USD 8.1B 645M Jun/2026
Dentsply International USD 1.18B 22M Jun/2026
General Electric Aerospace USD 40.43B 403M Jun/2026
Henry Schein USD 3.49B 191M Jun/2026
Illumina USD 1.58B 12M Jun/2026
IQVIA Holdings USD 8.82B 486M Jun/2026
Mettler Toledo International USD 1.2B 92.14M Jun/2026
Myriad Genetics USD 130.7M 500K Jun/2026
OraSure Technologies USD 25.12M 18.96M Jun/2026
Pacific Biosciences Of California USD 68.81M 3.45M Jun/2026
Pfizer USD 32.65B 1.7B Jun/2026
Repligen USD 132.66M 6.45M Jun/2026
Revvity USD 1.28B 37.71M Jun/2026
Standard Biotools USD 42.2M 66.1M Mar/2026
Thermo Fisher Scientific USD 15.07B 448M Jun/2026
Waters USD 2.27B 1.03B Mar/2026
West Pharmaceutical Services USD 640.5M 33.5M Jun/2026